The role of myokines in cancer: crosstalk between skeletal muscle and tumor

키워드

참고문헌 (121)

1. Frontera WR, "Skeletal muscle : a brief review of structure and function", Calcif Tissue Int, 96, pp.183~195 (2015)
2. Cohen S, "Muscle wasting in disease : molecular mechanisms and promising therapies", Nat Rev Drug Discov, 14, pp.58~74 (2015)
3. Prokopidis K, "Sarcopenia is associated with a greater risk of polypharmacy and number of medications : a systematic review and metaanalysis", J Cachexia Sarcopenia Muscle, 14, pp.671~683 (2023)
4. Iizuka K, "Skeletal muscle is an endocrine organ", J Pharmacol Sci, 125, pp.125~131 (2014)
5. Pedersen BK, "Muscles, exercise and obesity : skeletal muscle as a secretory organ", Nat Rev Endocrinol, 8, pp.457~465 (2012)
6. Severinsen MCK, "Muscle-organ crosstalk : the emerging roles of myokines", Endocr Rev, 41, pp.594~609 (2020)
7. Argiles JM, "Cachexia and sarcopenia : mechanisms and potential targets for intervention", Curr Opin Pharmacol, 22, pp.100~106 (2015)
8. Baracos VE, "Cancer-associated cachexia", Nat Rev Dis Primers, 4, pp.17105~ (2018)
9. Ali S, "Sarcopenia, cachexia and aging : diagnosis, mechanisms and therapeutic options-a mini-review", Gerontology, 60, pp.294~305 (2014)
10. Greten FR, "Inflammation and cancer : triggers, mechanisms, and consequences", Immunity, 51, pp.27~41 (2019)
11. Narsale AA, "Role of interleukin-6in cachexia : therapeutic implications", Curr Opin Support Palliat Care, 8, pp.321~327 (2014)
12. Patel HJ, "TNF-alpha and cancer cachexia : molecular insights and clinical implications", Life Sci, 170, pp.56~63 (2017)
13. Karayiannakis AJ, "Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients", Anticancer Res, 21, pp.1355~1358 (2001)
14. Okada S, "Elevated serum interleukin-6 levels in patients with pancreatic cancer", Jpn J Clin Oncol, 28, pp.12~15 (1998)
15. Srdic D, "Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value", Support Care Cancer, 24, pp.4495~4502 (2016)
16. Bilir C, "The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia", Med Oncol, 32, pp.56~ (2015)
17. Utech AE, "Predicting survival in cancer patients : the role of cachexia and hormonal, nutritional and inflammatory markers", J Cachexia Sarcopenia Muscle, 3, pp.245~251 (2012)
18. Matsuyama T, "Tumor inoculation site affects the development of cancer cachexia and muscle wasting", Int J Cancer, 137, pp.2558~2565 (2015)
19. Rupert JE, "Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia", J Exp Med, 218, pp.e20190450~ (2021)
20. Pototschnig I, "Interleukin-6initiates muscle-and adipose tissue wasting in a novel C57BL", 6 model of cancer-associated cachexia, 2023, pp.14, 93~107
21. Kang EA, "Amelioration of cancer cachexia with preemptive administration of tumor necrosis factor-alpha blocker", J Clin Biochem Nutr, 70, pp.117~128 (2022)
22. Choi MH, "Sarcopenia in pancreatic cancer : effect on patient outcomes", World J Gastrointest Oncol, 14, pp.2302~2312 (2022)
23. Fang P, "The prognostic value of sarcopenia in oesophageal cancer : a systematic review and meta-analysis", J Cachexia Sarcopenia Muscle, 14, pp.3~16 (2023)
24. Omori A, "Effects of changes in skeletal muscle mass on the prognosis of pediatric malignant solid tumors", Pediatr Surg Int, 38, pp.1829~1838 (2022)
25. Becker JN, "Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy", PLoS One, 18, pp.e0282015~ (2023)
26. de Jong C, "The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients", J Cachexia Sarcopenia Muscle, 13, pp.1554~1564 (2022)
27. Surov A, "Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis", Clin Nutr, 40, pp.5298~5310 (2021)
28. Murphy KT, "Mechanisms of chemotherapy-induced muscle wasting in mice with cancer cachexia", JCSM Rapid Communications, 5, pp.102~116 (2021)
29. Cortellini A, "Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1", PD-L1 checkpoint inhibitors : a multicenter real-life study, 2020, pp.10, 1456~
30. Li S, "Sarcopenia was a poor prognostic predictor for patients with advanced lung cancer treated with immune checkpoint inhibitors", Front Nutr, 9, pp.900823~ (2022)
31. Hoffmann C, "Skeletal muscle as an endocrine organ : the role of myokines in exercise adaptations", Cold Spring Harb Perspect Med, 7, pp.a029793~ (2017)
32. McTiernan A, "Physical activity in cancer prevention and survival : a systematic review", Med Sci Sports Exerc, 51, pp.1252~1261 (2019)
33. Moore SC, "Association of leisure-time physical activity with risk of 26 types of cancer in 1. 44 million adults", JAMA Intern Med, 176, pp.816~825 (2016)
34. Aoi W, "A novel myokine, secreted protein acidic and rich in cysteine(SPARC), suppresses colon tumorigenesis via regular exercise", Gut, 62, pp.882~889 (2013)
35. Jin-Soo Kim, "Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer", Prostate Cancer and Prostatic Diseases, 26(4), pp.795~801 (2022), Springer Science and Business Media LLC[DOI]
36. Kim J-S, "Exercise-induced myokines and their effect on prostate cancer", Nat Rev Urol, 18, pp.519~542 (2021)
37. Huang Q, "Muscle-to-tumor crosstalk : the effect of exercise-induced myokine on cancer progression", Biochim Biophys Acta Rev Cancer, 1877, pp.188761~ (2022)
38. Boström P, "A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis", Nature, 481, pp.463~468 (2012)
39. Huh JY, "FNDC5and irisin in humans : I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise", Metabolism, 61, pp.1725~1738 (2012)
40. Provatopoulou X, "Serum irisin levels are lower in patients with breast cancer : association with disease diagnosis and tumor characteristics", BMC Cancer, 15, pp.898~ (2015)
41. Pazgan-Simon M, "Serum concentrations of selected adipokines in virus-related liver cirrhosis and hepatocellular carcinoma", Clin Exp Hepatol, 6, pp.235~242 (2020)
42. Gannon NP, "Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro", Int J Cancer, 136, pp.197~202 (2015)
43. Shao L, "Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition", Biochem Biophys Res Commun, 485, pp.598~605 (2017)
44. Zhang Y, "Epithelial-to-mesenchymal transition in cancer : complexity and opportunities", Front Med, 12, pp.361~373 (2018)
45. Xu L, "Low FNDC5", Irisin expression is associated with aggressive phenotypes in gastric cancer, 2022, pp.13, 981201~
46. Alizadeh Zarei M, "Effects of the exerciseinducible myokine irisin on proliferation and malignant properties of ovarian cancer cells through the HIF-1 alpha signaling pathway", Sci Rep, 13, pp.170~ (2023)
47. Huang CW, "Irisin, an exercise myokine, potently suppresses tumor proliferation, invasion, and growth in glioma", FASEB J, 34, pp.9678~9693 (2020)
48. Esawy MM, "The diagnostic and prognostic roles of serum irisin in bladder cancer", Curr Probl Cancer, 44, pp.100529~ (2020)
49. Sofeu Feugaing DD, "More than matrix : the multifaceted role of decorin in cancer", Eur J Cell Biol, 92, pp.1~11 (2013)
50. Heinemeier KM, "Expression of extracellular matrix components and related growth factors in human tendon and muscle after acute exercise", Scand J Med Sci Sports, 23, pp.150~161 (2013)
51. Kanzleiter T, "The myokine decorin is regulated by contraction and involved in muscle hypertrophy", Biochem Biophys Res Commun, 450, pp.1089~1094 (2014)
52. Neill T, "Decoding the matrix : instructive roles of proteoglycan receptors", Biochemistry, 54, pp.4583~4598 (2015)
53. Bi X, "Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice", Carcinogenesis, 33, pp.326~330 (2012)
54. Hu X, "Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer", Commun Biol, 4, pp.72~ (2021)
55. Chen H, "Decorin inhibits proliferation and metastasis in human bladder cancer cells by upregulating P21", Medicine(Baltimore), 101, pp.e29760~ (2022)
56. Jia Y, "Decorin suppresses invasion and EMT phenotype of glioma by inducing autophagy via c-Met", Akt, Front Oncol, pp.2021, 11[DOI]
57. Buraschi S, "Decorin antagonizes Met receptor activity and down-regulates beta-catenin and Myc levels", J Biol Chem, 285, pp.42075~42085 (2010)
58. Reed CC, "Decorin prevents metastatic spreading of breast cancer", Oncogene, 24, pp.1104~1110 (2005)
59. Grant DS, "Decorin suppresses tumor cell-mediated angiogenesis", Oncogene, 21, pp.4765~4777 (2002)
60. Basak D, "Reciprocal interplay between asporin and decorin : implications in gastric cancer prognosis", PLoS One, 16, pp.e0255915~ (2021)
61. Troup S, "Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in nodenegative invasive breast cancer", Clin Cancer Res, 9, pp.207~214 (2003)
62. Di Sabatino A, "Role of IL-15 in immune-mediated and infectious diseases", Cytokine Growth Factor Rev, 22, pp.19~33 (2011)
63. Tamura Y, "Upregulation of circulating IL-15by treadmill running in healthy individuals : is IL-15 an endocrine mediator of the beneficial effects of endurance exercise?", Endocr J, 58, pp.211~215 (2011)
64. Riechman SE, Balasekaran G, Roth SM and Ferrell RE, "Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses", J Appl Physiol(1985)97 (2004)
65. Nielsen AR, "Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition", J Physiol, 584, pp.305~312 (2007)
66. Luo Z, "Exercise-induced IL-15acted as a positive prognostic implication and tumor-suppressed role in pan-cancer", Front Pharmacol, 13, pp.1053137~ (2022)
67. Reyes AF, "Tracking fluorescently labeled IL-15 and anti-PD-1 in the tumor microenvironment and draining lymph nodes", J Immunol Methods, 505, pp.113253~ (2022)
68. Stravokefalou V, "Heterodimeric IL-15(hetIL-15)reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC", Front Immunol, 13, pp.1014802~ (2022)
69. Miljkovic MD, "Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies", Blood Adv, 7, pp.384~394 (2023)
70. Kurz E, "Exercise-induced engagement of the IL-15", IL-15Ralpha axis promotes antitumor immunity in pancreatic cancer, 2022, pp.40, 720~737
71. Bradshaw AD, "SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury", J Clin Invest, 107, pp.1049~1054 (2001)
72. Miyamoto T, "Effects of exercise intensity and duration on a myokine, secreted protein acidic and rich in cysteine", Eur J Sport Sci, 22, pp.1401~1410 (2022)
73. Matsuo K, "A mechanism underlying preventive effect of high-intensity training on colon cancer", Med Sci Sports Exerc, 49, pp.1805~1816 (2017)
74. Yiu GK, "SPARC(secreted protein acidic and rich in cysteine)induces apoptosis in ovarian cancer cells", Am J Pathol, 159, pp.609~622 (2001)
75. Brekken RA, "Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM", J Clin Invest, 111, pp.487~495 (2003)
76. Schultz C, "Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo", Cancer Res, 62, pp.6270~6277 (2002)
77. Puolakkainen PA, "Enhanced growth of pancreatic tumors in SPARCnull mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis", Mol Cancer Res, 2, pp.215~224 (2004)
78. Ma J, "SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelialmesenchymal transition and apoptosis", Biochem Biophys Res Commun, 558, pp.134~140 (2021)
79. Zhang JL, "Secreted protein acidic and rich in cysteine(SPARC)suppresses angiogenesis by down-regulating the expression of VEGF and MMP-7 in gastric cancer", PLoS One, 7, pp.e44618~ (2012)
80. Said N, "The role of SPARC in the TRAMP model of prostate carcinogenesis and progression", Oncogene, 28, pp.3487~3498 (2009)
81. Rahman M, "A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo", PLoS One, 6, pp.e26390~ (2011)
82. Feng J, "SPARC in tumor pathophysiology and as a potential therapeutic target", Curr Pharm Des, 20, pp.6182~6190 (2014)
83. Grant JL, "A novel molecular pathway for snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis", Cancer Prev Res(Phila), 7, pp.150~160 (2014)
84. Lopez-Moncada F, "SPARC induces E-cadherin repression and enhances cell migration through integrin alphavbeta3 and the transcription factor ZEB1 in prostate cancer cells", Int J Mol Sci, 23, pp.5874~ (2022)
85. Tichet M, "Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis", Nat Commun, 6, pp.6993~ (2015)
86. Gao ZW, "SPARC Overexpression promotes liver cancer cell proliferation and tumor growth", Front Mol Biosci, 8, pp.775743~ (2021)
87. Pan K, "SPARC promotes pancreatic cancer cell proliferation and migration through autocrine secretion into the extracellular milieu", Oncol Lett, 21, pp.485~ (2021)
88. Arnold SA, "SPARC : a matricellular regulator of tumorigenesis", J Cell Commun Signal, 3, pp.255~273 (2009)
89. Neuzillet C, "Stromal expression of SPARC in pancreatic adenocarcinoma", Cancer Metastasis Rev, 32, pp.585~602 (2013)
90. Richards CD, "The enigmatic cytokine oncostatin m and roles in disease", ISRN Inflamm, 2013, pp.512103~ (2013)
91. Hwang JH, "Mobilizing serum factors and immune cells through exercise to counteract age-related changes in cancer risk", Exerc Immunol Rev, 26, pp.80~99 (2020)
92. Pan CM, "Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings", Oncotarget, 7, pp.60395~ (2016)
93. Grant SL, "An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells", Oncogene, 21, pp.460~474 (2002)
94. Halfter H, "Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression", Cancer Res, 66, pp.6530~6539 (2006)
95. Friedrich M, "Complete inhibition of in vivo glioma growth by oncostatin M", J Neurochem, 76, pp.1589~1592 (2001)
96. Kim JS, "Myokine expression and tumor-suppressive effect of serum after 12 wk of exercise in prostate cancer patients on ADT", Med Sci Sports Exerc, 54, pp.197~ (2022)
97. Hojman P, "Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth", Am J Physiol Endocrinol Metab, 301, pp.E504~E510 (2011)
98. Wang ML, "Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect", Cancer Res, 72, pp.6051~6064 (2012)
99. Tripathi C, "Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin", Oncotarget, 5, pp.5350~5368 (2014)
100. Araujo AM, "Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment", J Clin Invest, 132, pp.148667~ (2022)
101. Li Q, "Oncostatin M promotes proliferation of ovarian cancer cells through signal transducer and activator of transcription 3", Int J Mol Med, 28, pp.101~108 (2011)
102. Mori S, "Oncostatin M(OM)promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor", Anticancer Res, 19, pp.1011~1015 (1999)
103. Smigiel JM, "Potent EMT and CSC phenotypes are induced by oncostatin-M in pancreatic cancer", Mol Cancer Res, 15, pp.478~488 (2017)
104. Kucia-Tran JA, "Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival", Br J Cancer, 115, pp.212~222 (2016)
105. Smith DA, "Interleukin-6 and oncostatin-M synergize with the PI3K", AKT pathway to promote aggressive prostate malignancy in mouse and human tissues, 2013, pp.11, 1159~1165
106. Lapeire L, "Cancerassociated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak", STAT3 signaling, 2014, pp.74, 6806~6819
107. Lacreusette A, "Loss of oncostatin M receptor beta in metastatic melanoma cells", Oncogene, 26, pp.881~892 (2007)
108. Bathina S, "Brain-derived neurotrophic factor and its clinical implications", Arch Med Sci, 11, pp.1164~1178 (2015)
109. Gomez-Pinilla F, "Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity", J Neurophysiol, 88, pp.2187~2195 (2002)
110. Clow C, "Brain-derived neurotrophic factor regulates satellite cell differentiation and skeltal muscle regeneration", Mol Biol Cell, 21, pp.2182~2190 (2010)
111. Miknyoczki SJ, "Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma : expression patterns and effects on in vitro invasive behavior", Int J Cancer, 81, pp.417~427 (1999)
112. Sinkevicius KW, "Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis", Proc Natl Acad Sci U S A, 111, pp.10299~10304 (2014)
113. Shen T, "Erlotinib inhibits colon cancer metastasis through inactivation of TrkBdependent ERK signaling pathway", J Cell Biochem, 120, pp.11248~11255 (2019)
114. Zhang SY, "More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells", BMC Cancer, 16, pp.171~ (2016)
115. Matthews VB, "Brainderived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase", Diabetologia, 52, pp.1409~1418 (2009)
116. Ibeas K, "Hypothalamus-skeletal muscle crosstalk during exercise and its role in metabolism modulation", Biochem Pharmacol, 190, pp.114640~ (2021)
117. Xiao R, "Environmental and genetic activation of hypothalamic BDNF modulates T-cell immunity to exert an anticancer phenotype", Cancer Immunol Res, 4, pp.488~497 (2016)
118. Cao L, "Environmental and genetic activation of a brain-adipocyte BDNF", leptin axis causes cancer remission and inhibition, 2010, pp.142, 52~64
119. Garofalo S, "Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice", Nat Commun, 6, pp.6623~ (2015)
120. Fang P, "Adipose-muscle crosstalk in age-related metabolic disorders : the emerging roles of adipo-myokines", Ageing Res Rev, 84, pp.101829~ (2023)
121. Jena BP, "Understanding brain-skeletal muscle crosstalk impacting metabolism and movement", Discoveries(Craiova), 10, pp.e144~ (2022)

관련 논문AI추천